Sitagliptin Phosphate and Dapagliflozin . . . . .. .

ST-GLIPTIN DAPA 100/10 is a modern oral antidiabetic medication that combines Sitagliptin Phosphate and Dapagliflozin in a single tablet. This advanced combination therapy is prescribed for the management of Type 2 Diabetes Mellitus (T2DM) in adults, especially in patients who require better glycaemic control beyond diet, exercise, or single-drug therapy.

Type 2 diabetes is a growing public health concern in India, driven by sedentary lifestyles, unhealthy dietary habits, obesity, and genetic predisposition. Poorly controlled diabetes can lead to serious long-term complications such as heart disease, kidney failure, nerve damage, vision loss, and recurrent infections. Hence, early and effective blood sugar control is critical.

ST-GLIPTIN DAPA 100/10 addresses multiple defects involved in Type 2 diabetes. Sitagliptin improves insulin secretion and suppresses excess glucagon release, while Dapagliflozin removes excess glucose through urine by acting on the kidneys. This dual mechanism offers complementary and sustained blood glucose control with a low risk of hypoglycaemia when used appropriately.

Uses of ST-GLIPTIN DAPA 100/10

Sitagliptin Phosphate and Dapagliflozin is primarily indicated for the treatment of Type 2 Diabetes Mellitus in adults.

1. Control of Blood Sugar Levels

• Reduces fasting blood glucose

• Controls post-meal (postprandial) blood sugar spikes

• Helps maintain long-term glycaemic stability

2. Management of Type 2 Diabetes Not Controlled by Monotherapy

• Ideal for patients inadequately controlled on metformin or other oral antidiabetics

• Can be used as part of combination therapy under medical supervision

3. Improvement in Insulin Function

• Enhances insulin release in a glucose-dependent manner

• Reduces insulin resistance indirectly

4. Support in Weight-Neutral or Weight-Reducing Therapy

• Dapagliflozin may assist in modest weight reduction

• Suitable for overweight or obese diabetic patients

5. Reduction of Diabetes-Related Complications

• Helps reduce the risk of cardiovascular and kidney complications associated with uncontrolled diabetes

Benefits of ST-GLIPTIN DAPA 100/10

1. Dual Mechanism of Action

ST-GLIPTIN DAPA 100/10 works through two different pathways:

• Sitagliptin (DPP-4 inhibitor) increases incretin hormones, improving insulin secretion and reducing glucagon levels.

• Dapagliflozin (SGLT-2 inhibitor) promotes glucose excretion through urine, lowering blood sugar independently of insulin.

This complementary action ensures effective and sustained glycaemic control.

2. Lower Risk of Hypoglycaemia

Since Sitagliptin works in a glucose-dependent manner and Dapagliflozin does not stimulate insulin release directly, the risk of low blood sugar is comparatively lower when used alone or with non-insulin therapies.

3. Weight and Blood Pressure Benefits

• Dapagliflozin may contribute to mild weight loss

• Promotes mild reduction in blood pressure due to osmotic diuresis

4. Kidney and Heart Protective Potential

Clinical studies suggest SGLT-2 inhibitors like Dapagliflozin may offer renal and cardiovascular benefits in suitable patients.

5. Improved Treatment Adherence

A single-tablet combination reduces pill burden, improving patient compliance and convenience in long-term therapy.

6. Suitable for Long-Term Diabetes Management

When used with regular monitoring, ST-GLIPTIN DAPA 100/10 is suitable for chronic diabetes care.

Dosage of ST-GLIPTIN DAPA 100/10

The dosage of ST-GLIPTIN DAPA 100/10 should be strictly as advised by a qualified healthcare professional.

Recommended Dosage

• Usually one tablet once daily, with or without food

• Taken at the same time each day for best results

Administration Guidelines

• Swallow the tablet whole with water

• Do not crush or chew

• Maintain adequate hydration while on therapy

Dose Adjustment

• Dosage may be adjusted in elderly patients

• Not recommended in patients with severe renal impairment unless advised by a specialist

Monitoring

• Regular monitoring of fasting blood sugar, postprandial blood sugar, and HbA1c

• Periodic kidney function tests are recommended

Side Effects of ST-GLIPTIN DAPA 100/10

Like all medicines, Sitagliptin Phosphate and Dapagliflozin may cause side effects in some patients, although many people tolerate it well.

Common Side Effects

• Increased urination

• Thirst

• Headache

• Nasopharyngitis (common cold-like symptoms)

Less Common Side Effects

• Urinary tract infections

• Genital fungal infections

• Mild dizziness or weakness

Rare but Serious Side Effects

• Dehydration

• Severe urinary infections

• Pancreatitis (rare)

• Allergic reactions such as rash or swelling

Patients should seek immediate medical attention if they experience severe or persistent symptoms.

Warnings for ST-GLIPTIN DAPA 100/10

• Not indicated for Type 1 Diabetes or diabetic ketoacidosis

• Use caution in patients with kidney disease

• Increased risk of urinary and genital infections

• Not recommended during pregnancy and breastfeeding unless clearly advised by a doctor

• Excessive alcohol consumption should be avoided

• Inform your doctor about all other medications being taken

Conclusion

ST-GLIPTIN DAPA 100/10 (Sitagliptin Phosphate & Dapagliflozin) represents a modern, dual-action approach to managing Type 2 Diabetes Mellitus. By addressing multiple pathways involved in blood glucose regulation, it provides effective glycaemic control with added benefits such as low hypoglycaemia risk, weight neutrality, and potential cardiovascular and renal support.

Precautions & Frequently Asked Questions (FAQs)

Precautions

• Maintain good personal hygiene to reduce infection risk

• Stay adequately hydrated

• Monitor blood sugar regularly

• Follow a balanced diabetic diet and exercise plan

• Do not stop the medicine abruptly without consulting your doctor

Frequently Asked Questions (FAQs)

Q1. What is ST-GLIPTIN DAPA 100/10 used for?
It is used for the treatment of Type 2 Diabetes Mellitus to control blood sugar levels effectively.

Q2. Does ST-GLIPTIN DAPA 100/10 cause weight gain?
No. Dapagliflozin may help in modest weight reduction in some patients.

Q3. Can ST-GLIPTIN DAPA 100/10 cause hypoglycaemia?
The risk is low when taken alone, but it may increase if combined with insulin or sulfonylureas.

Q4. Is this medicine safe for long-term use?
Yes, when used under medical supervision with regular monitoring.

Q5. Can elderly patients take ST-GLIPTIN DAPA 100/10?
Yes, but kidney function should be monitored closely.

Q6. What should I do if I miss a dose?
Take it as soon as you remember. If it is close to the next dose, skip the missed dose and continue as normal.